Enanta Pharmaceuticals, Inc. (ENTA) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 14 Buy, 3 Hold, 2 Sell.
The consensus price target is $48.20 (low: $20.00, high: $87.00), representing an upside of 229.5% from the current price $14.63.
Analysts estimate Earnings Per Share (EPS) of $-5.28 and revenue of $0.07B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.48 vs est $-5.28 (missed -3.8%). 2025: actual $-3.84 vs est $-3.77 (missed -1.8%). Analyst accuracy: 97%.
ENTA Stock — 12-Month Price Forecast
$48.20
▲ +229.46% Upside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for Enanta Pharmaceuticals, Inc., the average price target is $48.20, with a high forecast of $87.00, and a low forecast of $20.00.
The average price target represents a +229.46% change from the last price of $14.63.
Highest Price Target
$87.00
Average Price Target
$48.20
Lowest Price Target
$20.00
ENTA Analyst Ratings
Buy
Based on 19 analysts giving stock ratings to Enanta Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ENTA
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$5.48
vs Est –$5.28
▼ 3.6% off
2025
Actual –$3.84
vs Est –$3.77
▼ 1.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ENTA
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.068B
vs Est $0.071B
▼ 5.3% off
2025
Actual $0.065B
vs Est $0.066B
▼ 1.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
